m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00416)
Name
C[Nle-Pro-D-Nal(2')-Arg-Trp-Glu]-NH2
Synonyms
CHEMBL203760; BDBM50184366
    Click to Show/Hide
Status
Investigative
Structure
3D MOL
2D MOL
Formula
C46H59N11O7
InChI
1S/C46H59N11O7/c1-2-3-13-35-45(64)57-22-9-16-38(57)44(63)56-36(24-27-17-18-28-10-4-5-11-29(28)23-27)42(61)54-34(15-8-21-50-46(48)49)41(60)55-37(25-30-26-51-32-14-7-6-12-31(30)32)43(62)53-33(40(47)59)19-20-39(58)52-35/h4-7,10-12,14,17-18,23,26,33-38,51H,2-3,8-9,13,15-16,19-22,24-25H2,1H3,(H2,47,59)(H,52,58)(H,53,62)(H,54,61)(H,55,60)(H,56,63)(H4,48,49,50)/t33-,34-,35-,36+,37-,38-/m0/s1
InChIKey
QQCJWXXVYXUARZ-ZPRVLUMXSA-N
PubChem CID
11629326
TTD Drug ID
D0P4GI
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Melanocortin receptor 4 (MC4R)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Melanocortin receptor 4 (MC4R) is a therapeutic target for C[Nle-Pro-D-Nal(2')-Arg-Trp-Glu]-NH2. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of C[Nle-Pro-D-Nal(2')-Arg-Trp-Glu]-NH2 through regulating the expression of Melanocortin receptor 4 (MC4R). [1], [2]
References
Ref 1 Demethyltransferase FTO alpha-ketoglutarate dependent dioxygenase (FTO) regulates the proliferation, migration, invasion and tumor growth of prostate cancer by modulating the expression of melanocortin 4 receptor (MC4R). Bioengineered. 2022 Mar;13(3):5598-5612. doi: 10.1080/21655979.2021.2001936.
Ref 2 Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. doi: 10.1021/jm0510326.